FDA Approves neffy (epinephrine nasal spray) Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

FDA approves neffy (epinephrine nasal spray) 2 mg for Type I Allergic Reactions, including anaphylaxis, in adults and children ≥30 kg, marking the first needle-free epinephrine treatment innovation in over 35 years.


Highlighted Terms

University of Washington School of MedicineARS Pharmaceuticals, Inc.FDAfood allergyepinephrineantihistaminesanaphylaxisneffy 2 mgneffy 1 mgHealioSECARS PharmaceuticalsSECtype 1 allergic reactionsepinephrine injectionType I Allergic ReactionsNo Patient Left Behindepinephrine nasal spraySam Brown Inc.anaphylaxisMassachusetts General HospitalneffyHarvard Medical SchoolepinephrineepinephrineFDASecurities and Exchange CommissionUS Food and Drug Administrationepinephrine auto-injectorFood Allergy Research and Educationchronic urticariaType I Allergic ReactionsARS Pharmaceuticalsanaphylaxisneffy 2 mgUSF Health Morsani College of MedicineARS PharmaceuticalsAsthma and Allergy Foundation of Americasevere allergic reactionsARS PharmaceuticalsFood Allergy & Anaphylaxis Connection TeamSecurities and Exchange Commissionneffyneffy 1 mganaphylaxisanaphylaxisepinephrine nasal spraycorticosteroidsFAREUS FDAepinephrine nasal sprayanaphylaxisCHOICE Institutetype 1 allergic reactionsType 1 Allergic Reactionsepinephrineneffy 2 mgneffyurticariaepinephrineFDASchool of Pharmacy at the University of WashingtonFood Allergy & Anaphylaxis Connection TeamFAACTepinephrine nasal sprayNo Nut TravelerEuropean CommissionType I Allergic ReactionsBlinkRxFood Allergy & Anaphylaxis Connection TeamanaphylaxisUniversity of South FloridaepinephrineARS Pharmaceuticalsepinephrine auto-injectorFAACTneffy 1 mgneffyneffyanaphylaxisType I Allergic Reactionsadrenaline nasal sprayepinephrine nasal sprayAmerican Academy of Allergy, Asthma and ImmunologyneffyChildren's Hospital of PhiladelphianeffyU.S. Food and Drug Administrationepinephrine nasal spraySam Brown Inc.

Related News

FDA Fast-Tracks First Nasal Spray for Allergic Reactions, Anaphylaxis - JAMA Network

FDA approves neffy, the first epinephrine nasal spray for treating anaphylaxis in adults and children over 30 kg. Studies show comparable blood epinephrine levels to injections. Administered via a single nostril spray, with a second dose if needed. Common side effects include throat irritation, nasal tingling, and headaches. Addresses fear of injections in some patients.

ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with ...

ARS Pharmaceuticals submits sNDA for neffy 1 mg, a needle-free epinephrine treatment for children 15-30 kg, following FDA approval of neffy 2 mg in 2024.

Q&A: Company seeks to expand neffy FDA approval to more pediatric patients - Healio

ARS Pharmaceuticals submitted an FDA application for neffy 1 mg to treat type 1 allergic reactions in children weighing 33-66 lb, following approval for adults in August. The nasal spray aims to eliminate needle fear and accidental injuries, with studies showing children as young as 10 can self-administer. ARS is also developing nasal sprays for other type 1 hypersensitivity reactions, including urticaria.

FDA Approves neffy (epinephrine nasal spray) Needle-Free Treatment for Type I Allergic Reactions, Including Anaphylaxis

FDA approves neffy (epinephrine nasal spray) 2 mg for Type I Allergic Reactions, including anaphylaxis, in adults and children ≥30 kg, marking the first needle-free epinephrine treatment innovation in over 35 years.

sNDA Goes to FDA for neffy 1 mg for Young Children with Type 1 Allergic Reactions

ARS Pharmaceuticals submits sNDA to FDA for neffy 1 mg nasal spray for treating type 1 allergic reactions in children 15-30 kg, aiming to address needle phobia and improve emergency treatment access.

ARS Pharmaceuticals Submits sNDA to FDA for neffy® 1 mg Dose for Pediatric Patients with ...

ARS Pharmaceuticals submits sNDA for neffy 1 mg, a needle-free epinephrine treatment for children 15-30 kg, aiming to address needle fear and improve emergency treatment for Type I Allergic Reactions, including anaphylaxis.

ARS Pharmaceuticals Announces U.S. Availability of neffy® (epinephrine nasal spray), the ...

ARS Pharmaceuticals announces the U.S. availability of neffy® (epinephrine nasal spray) for treating Type I Allergic Reactions, including anaphylaxis, in adults and children weighing ≥30 kg. neffy is accessible through various programs, including a $25 co-pay for insured patients and a $199 cash price for uninsured patients. ARS also plans to expand access to EURneffy® in the EU by Q4 2024 and has submitted an FDA application for pediatric use.

New Needle-Free Epinephrine Nasal Spray a 'Game Changer' - WebMD

FDA approves neffy, a needle-free nasal spray epinephrine for treating anaphylaxis in adults and children over 66 lbs, addressing fears of needles and auto-injector use. Expected to be available in late October, priced at $199 for a two-pack, with insurance co-pays at $25. ARS plans to seek FDA approval for children 30-66 lbs later this year.

© Copyright 2024. All Rights Reserved by MedPath